Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · VIMTALABS

VIMTA LABS

HealthcareHealthcare Services₹2084 cr market cap
₹471.95 ▲ +1.1% today As of 19 Nov 2026
52-week low ₹380.7052-week high ₹661.75

-29.5% from the 52-week high · +22.6% above the low

Vimta Labs Ltd. engages in the provision of contract research and testing. The company is headquartered in Hyderabad, Telangana and currently employs 1,368 full-time employees. The firm is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include Drug discovery, development, and drug life cycle management support services; Preclinical research and testing services for medical device companies; Contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; Clinical diagnostics services to patients, clinicians, and hospitals, and environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure.

The short version. VIMTA LABS reported revenue of ₹90 crore for Dec 2024, up 9.8% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Promoter holding was 35.64% in Sep 2026, down 1.12 points over 8 quarters.

1 · The price

How has the stock traded?

VIMTA LABS trades 29.5% below its 52-week high and 22.6% above its 52-week low.

Change over period: —

1M-7.5%
3M-24.9%
6M+3.8%
1Y-24.8%

2 · The business

Is it growing?

Sales, year on year+9.8%

Dec 2024 revenue of ₹90 cr.

Profit, year on year+110.0%

Dec 2024 net profit of ₹21 cr.

Net margin23.9%

11.5 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Revenue9085828082738382
Net profit211512121061213
Net margin %23.918.015.015.512.48.614.615.5
EPS (₹)4.843.442.772.792.291.432.752.87

Annual

FY2024FY2023FY2022FY2021FY2020FY2019
Revenue318318278211181213
Net profit41484121725
Net margin %12.915.114.910.23.811.9
EPS (₹)9.2510.889.354.841.555.72

3 · The quality

How well does it turn capital into profit?

.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %——12.817.1
Return on capital %——16.422.2
EBITDA margin %——28.230.6
Net margin %——12.715.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
P/E ratio26.2

4 · The owners

Who holds it, and are they adding?

Promoter holding35.64%

Down 1.12 pts over 8 quarters.

Foreign institutions5.07%

Up 1.26 pts over 8 quarters.

Domestic institutions0.48%

Down 0.68 pts over 8 quarters.

Mutual fund schemes3

+1 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter36.7636.736.6735.9935.935.8535.6735.64-1.12
FII3.813.663.494.334.594.894.425.07+1.26
DII1.161.431.420.870.110.140.370.48-0.68
Public58.2758.258.4258.859.4159.1259.5558.8+0.53

Mutual fund holdings · Oct 2026

3 schemes hold this stock

2 the month before.

  • WhiteOak Capital Pharma and Healthcare Fund0.52% of NAV
  • Motilal Oswal BSE Healthcare ETF0.05% of NAV
  • Bandhan BSE Healthcare Index Fund0.05% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for VIMTA LABS are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about VIMTA LABS

What is the VIMTA LABS share price?

VIMTA LABS (VIMTALABS) last closed at ₹471.95, up 1.1% on the day. Its 52-week range is ₹380.70 to ₹661.75.

What is the market cap of VIMTA LABS?

VIMTA LABS has a market capitalisation of about ₹2,084 crore. Its price-to-earnings ratio is 26.2.

How are VIMTA LABS's latest results?

VIMTA LABS reported revenue of ₹90 crore for Dec 2024, up 9.8% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Promoter holding was 35.64% in Sep 2026, down 1.12 points over 8 quarters.

Who owns VIMTA LABS?

As of Sep 2026, shareholding was: Promoter 35.64%, FII 5.07%, DII 0.48%, Public 58.8%.

How many mutual funds hold VIMTA LABS?

3 mutual fund schemes held VIMTA LABS in October 2026. That compares with 2 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Jun 2026 · Final Dividend - Rs. 2
  • 13 Jun 2025 · Bonus issue 1:1
  • 30 May 2025 · Dividend - Rs. 2
  • 11 Jul 2024 · Final Dividend - Rs. 2
  • 21 Jun 2023 · Final Dividend - Rs. 2
  • 16 Jun 2022 · Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.